Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 2
2008 5
2009 3
2011 1
2014 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sparc investigators[Corporate Author] (6 results)?
High-dose atorvastatin after stroke or transient ischemic attack.
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Amarenco P, et al. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894. N Engl J Med. 2006. PMID: 16899775 Free article. Clinical Trial.
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
Stroke Prevetion by Aggressive Reduction in Cholestrol Levels (SPARCL) Investigators; Karam JG, Loney-Hutchinson L, McFarlane SI. Stroke Prevetion by Aggressive Reduction in Cholestrol Levels (SPARCL) Investigators, et al. J Cardiometab Syndr. 2008 Winter;3(1):68-9. doi: 10.1111/j.1559-4572.2008.07967.x. J Cardiometab Syndr. 2008. PMID: 18326981 No abstract available.
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Amarenco P, et al. Atherosclerosis. 2009 Jun;204(2):515-20. doi: 10.1016/j.atherosclerosis.2008.09.008. Epub 2008 Sep 18. Atherosclerosis. 2009. PMID: 18962621 Clinical Trial.
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Amarenco P, et al. Stroke. 2007 Dec;38(12):3198-204. doi: 10.1161/STROKEAHA.107.493106. Epub 2007 Oct 25. Stroke. 2007. PMID: 17962589 Clinical Trial.
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM; SPARCL Investigators. Callahan A, et al. Arch Neurol. 2011 Oct;68(10):1245-51. doi: 10.1001/archneurol.2011.146. Epub 2011 Jun 13. Arch Neurol. 2011. PMID: 21670382 Clinical Trial.
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, Hennerici M, Sillesen H, Welch KM; SPARCL Investigators. Goldstein LB, et al. Stroke. 2008 Sep;39(9):2444-8. doi: 10.1161/STROKEAHA.107.513747. Epub 2008 Jul 10. Stroke. 2008. PMID: 18617654 Clinical Trial.
12 results